Thus, research efforts have focused on finding alternative therapies to trastuzumab and lapatinib for the treatment of Her2-positive breast cancer. Efforts aimed at understanding the mechanism of action of trastuzumab and lapatinib and the causes of resistance have led to the identification of several ...
The therapeutic landscape for HER2-positive metastatic breast cancer has exploded in the last two decades following the initial advent of trastuzumab, a monoclonal antibody. While the first line treatment has remained a combination of dual HER2 blockade with taxane chemotherapy, we now have several ex...
“There have been many advances in the development of drugs for HER2-positive breast cancer since the introduction of Herceptin (trastuzumab) in 1998. The approval of Enhertu represents the newest treatment option for patients who have progressed on available HER2-directed therapie...
In an interview with OncLive during the 35th annual CFS®, Tolaney, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discussed the state of adjuvant treatment for patients with HER2-positive breast cancer.Tolaney: [Adjuvant treatm...
HER2-positivetrastuzumabcost-benefit analysisquality of lifeHER2-positive disease is an aggressive subtype of breast cancer that has been revolutionized by anti-HER2 directed therapies. Multiple drugs have been developed and are currently in clinical use, including trastuzumab, lapatinib, pertuzumab, T-...
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were tr
The treatment of HER2-positive breast cancer has benefited from a number of targeted agents. Although adjuvant trastuzumab has dramatically reduced progression--making metastatic disease far less common today--newer treatment advances ar... Gradishar,J William - 《Journal of the National Comprehensive ...
In the first segment, Dr Pegram and colleagues highlight some of the challenges and remaining unmet needs in the management of patients with HER2-positive breast cancer.EP: 1.Examining the Unmet Needs in the Treatment of HER2-Positive Breast Cancer EP: 2.Treating Early-Stage HER2-Positive ...
Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer Background:;Trastuzumab emtansine (T-DM1), a novel drug developed for the treatment of HER2-positive breast cancer, is a human epidermal growth factor rece... B Boyraz,MAN Sendur,S Aksoy,... - 《Current Medical Research & Opinio...
Sara A. Hurvitz, MD, comments on her preferences for treating patients with HER2-positive metastatic breast cancer and shares her strategy for sequencing therapies. EP: 1.Treatment Options in HER2-Positive Metastatic Breast Cancer EP: 2.Tucatinib for HER2-Positive Metastatic Breast Cancer EP: 3....